Zymeworks Inc. (ZYME): R&D Expense

Annual figures by period end, from SEC filings.

$137.00M
Year ended 2025-12-31
$129.25M
Trailing 12 months to 2026-09-30
-13.1%
3-year compound annual growth
-4.4%
5-year compound annual growth
$208.60M2020-12-31: $171.20M2021-12-31: $199.75M2022-12-31: $208.60M2023-12-31: $143.62M2024-12-31: $134.62M2025-12-31: $137.00M$137.00M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$137.00M+1.8%2026-03-02, From 2025-01-01
2024-12-31$134.62M-6.3%2026-03-02, From 2024-01-01
2023-12-31$143.62M-31.1%2026-03-02, From 2023-01-01
2022-12-31$208.60M+4.4%2025-03-05, From 2022-01-01
2021-12-31$199.75M+16.7%2024-03-06, From 2021-01-01
2020-12-31$171.20Mn/a2023-03-07, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Zymeworks Inc. (ZYME)2025-12-31$137.00M+1.8%
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$12.74M-69.7%
UroGen Pharma Ltd. (URGN)2025-12-31$67.11M+17.4%
Gyre Therapeutics, Inc. (GYRE)2025-12-31$13.70M+13.9%
Siga Technologies Inc (SIGA)2025-12-31$19.96M+62.1%
Xencor Inc (XNCR)2025-12-31$239.43M+5.2%
Cytokinetics Inc (CYTK)2025-12-31$416.03M+22.6%
Lifecore Biomedical, Inc. (LFCR)2025-05-25$8.26M-3.7%
Standard Biotools Inc. (LAB)2025-12-31$25.99M-9.9%

Compare ZYME, ZVRA, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗